{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:29:38Z","timestamp":1773275378705,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15584-4","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:04:46Z","timestamp":1770332686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcome and dose intensity of Pola-R-CHP versus R-CHOP\/R-THP-COP in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Kei","family":"Fujita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Kajiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuji","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Nonogaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"9","key":"15584_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842\u201358. https:\/\/doi.org\/10.1056\/NEJMra2027612.","journal-title":"N Engl J Med"},{"issue":"4","key":"15584_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2115304.","journal-title":"N Engl J Med"},{"issue":"21","key":"15584_CR3","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1182\/blood.2020008239","volume":"141","author":"PJ Lugtenburg","year":"2023","unstructured":"Lugtenburg PJ, Mutsaers P. How I treat older patients with DLBCL in the frontline setting. Blood. 2023;141(21):2566\u201375. https:\/\/doi.org\/10.1182\/blood.2020008239.","journal-title":"Blood"},{"issue":"10","key":"15584_CR4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ajh.24819","volume":"92","author":"C Saygin","year":"2017","unstructured":"Saygin C, Jia X, Hill B, et al. Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. Am J Hematol. 2017;92(10):989\u201396. https:\/\/doi.org\/10.1002\/ajh.24819.","journal-title":"Am J Hematol"},{"issue":"1","key":"15584_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.16743","volume":"192","author":"S Lee","year":"2021","unstructured":"Lee S, Fujita K, Morishita T, et al. Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma. Br J Haematol. 2021;192(1):100\u20139. https:\/\/doi.org\/10.1111\/bjh.16743.","journal-title":"Br J Haematol"},{"issue":"3","key":"15584_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/onco.13641[publishedOnlineFirst:2020\/12\/16]","volume":"26","author":"K Oiwa","year":"2021","unstructured":"Oiwa K, Fujita K, Lee S, et al. Utility of the Geriatric 8 for the Prediction of Therapy-Related Toxicity in Older Adults with Diffuse Large B-Cell Lymphoma. Oncologist. 2021;26(3):215\u201323. https:\/\/doi.org\/10.1002\/onco.13641.","journal-title":"Oncologist"},{"issue":"4","key":"15584_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/joim.12849","volume":"285","author":"T W\u00e4sterlid","year":"2019","unstructured":"W\u00e4sterlid T, Mohammadi M, Smedby KE, et al. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study. J Intern Med. 2019;285(4):455\u201368. https:\/\/doi.org\/10.1111\/joim.12849.","journal-title":"J Intern Med"},{"issue":"2","key":"15584_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/bjh.17554","volume":"194","author":"S Lee","year":"2021","unstructured":"Lee S, Fujita K, Morishita T, et al. Association of the geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma. Br J Haematol. 2021;194(2):325\u201335. https:\/\/doi.org\/10.1111\/bjh.17554.","journal-title":"Br J Haematol"},{"key":"15584_CR9","doi-asserted-by":"publisher","unstructured":"Fujita K, Tsukasaki H, Lee S, et al. Age interaction in associations between geriatric nutritional risk index and prognosis in diffuse large B-cell lymphoma. Ann Hematol. 2025;104(11):5819-28. https:\/\/doi.org\/10.1007\/s00277-025-06477-w.","DOI":"10.1007\/s00277-025-06477-w"},{"issue":"6","key":"15584_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/jco.1990.8.6.963","volume":"8","author":"LW Kwak","year":"1990","unstructured":"Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8(6):963\u201377. https:\/\/doi.org\/10.1200\/jco.1990.8.6.963.","journal-title":"J Clin Oncol"},{"issue":"8","key":"15584_CR11","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.3324\/haematol.2019.234435","volume":"105","author":"S Lee","year":"2020","unstructured":"Lee S, Fujita K, Negoro E, et al. Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma. Haematologica. 2020;105(8):e415\u20138. https:\/\/doi.org\/10.3324\/haematol.2019.234435.","journal-title":"Haematologica"},{"issue":"9","key":"15584_CR12","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","volume":"5","author":"EJ Bataillard","year":"2021","unstructured":"Bataillard EJ, Cheah CY, Maurer MJ, et al. Impact of r-chop dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Adv. 2021;5(9):2426\u201337. https:\/\/doi.org\/10.1182\/bloodadvances.2021004665.","journal-title":"Blood Adv"},{"issue":"3","key":"15584_CR13","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/cam4.2008","volume":"8","author":"M D\u0142ugosz-Danecka","year":"2019","unstructured":"D\u0142ugosz-Danecka M, Szmit S, Og\u00f3rka T, et al. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. Cancer Med. 2019;8(3):1103\u20139. https:\/\/doi.org\/10.1002\/cam4.2008.","journal-title":"Cancer Med"},{"issue":"1","key":"15584_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00277-015-2514-9[publishedOnlineFirst:2015\/10\/06]","volume":"95","author":"Y Utsu","year":"2016","unstructured":"Utsu Y, Takaishi K, Inagaki S, et al. Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma. Ann Hematol. 2016;95(1):41\u20137. https:\/\/doi.org\/10.1007\/s00277-015-2514-9.","journal-title":"Ann Hematol"},{"issue":"3","key":"15584_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.clml.2020.12.017","volume":"21","author":"S Marshall","year":"2021","unstructured":"Marshall S, Nishimura N, Inoue N, et al. Impact of omission\/reduction of vincristine from R-CHOP in treatment of DLBCL. Clin Lymphoma Myeloma Leuk. 2021;21(3):162\u20139. https:\/\/doi.org\/10.1016\/j.clml.2020.12.017.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"15584_CR16","doi-asserted-by":"publisher","first-page":"e70017","DOI":"10.1002\/hon.70017","volume":"43","author":"P Zhao","year":"2025","unstructured":"Zhao P, Zhao S, Huang C, et al. Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: a real-world, multi-center, retrospective cohort study. Hematol Oncol. 2025;43(1):e70017. https:\/\/doi.org\/10.1002\/hon.70017.","journal-title":"Hematol Oncol"},{"key":"15584_CR17","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, fourth edition. IARC Press 2008."},{"key":"15584_CR18","doi-asserted-by":"publisher","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","DOI":"10.1182\/blood-2016-01-643569"},{"issue":"7","key":"15584_CR19","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"issue":"4","key":"15584_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342. https:\/\/doi.org\/10.1056\/NEJMoa011795.","journal-title":"N Engl J Med"},{"issue":"4","key":"15584_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/hon.2524","volume":"36","author":"T Hara","year":"2018","unstructured":"Hara T, Yoshikawa T, Goto H, et al. R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: a randomized, open-label, noninferiority phase 3 trial. Hematol Oncol. 2018;36(4):638\u201344. https:\/\/doi.org\/10.1002\/hon.2524.","journal-title":"Hematol Oncol"},{"issue":"6","key":"15584_CR22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00277-018-3273-1","volume":"97","author":"Y Kanemasa","year":"2018","unstructured":"Kanemasa Y, Shimoyama T, Sasaki Y, et al. Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. Ann Hematol. 2018;97(6):999\u20131007. https:\/\/doi.org\/10.1007\/s00277-018-3273-1.","journal-title":"Ann Hematol"},{"key":"15584_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06477-w","author":"K Fujita","year":"2025","unstructured":"Fujita K, Tsukasaki H, Lee S, et al. Age interaction in associations between geriatric nutritional risk index and prognosis in diffuse large B-cell lymphoma. Ann Hematol. 2025. https:\/\/doi.org\/10.1007\/s00277-025-06477-w.","journal-title":"Ann Hematol"},{"key":"15584_CR24","unstructured":"Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988:121\u201341."},{"issue":"3","key":"15584_CR25","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1080\/10428194.2016.1211279","volume":"58","author":"Y Kanemasa","year":"2017","unstructured":"Kanemasa Y, Shimoyama T, Sasaki Y, et al. The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58(3):736\u20139. https:\/\/doi.org\/10.1080\/10428194.2016.1211279.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"15584_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-008-0447-2","volume":"87","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87(5):429\u201330. https:\/\/doi.org\/10.1007\/s00277-008-0447-2.","journal-title":"Ann Hematol"},{"key":"15584_CR27","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0; US Department of Health and Human Services: Washington, DC, USA, 2017."},{"key":"15584_CR28","doi-asserted-by":"publisher","unstructured":"A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329(14):987\u201394. https:\/\/doi.org\/10.1056\/nejm199309303291402.","DOI":"10.1056\/nejm199309303291402"},{"key":"15584_CR29","unstructured":"R Core Team; R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing; R Core Team:Vienna, Austria, 2016."},{"issue":"10","key":"15584_CR30","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/bloodadvances.2024014707","volume":"9","author":"B Hu","year":"2025","unstructured":"Hu B, Reagan PM, Sehn LH, et al. Subgroup analysis of older patients \u226560 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Blood Adv. 2025;9(10):2489\u201399. https:\/\/doi.org\/10.1182\/bloodadvances.2024014707.","journal-title":"Blood Adv"},{"issue":"10","key":"15584_CR31","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1007\/s00277-025-06619-0","volume":"104","author":"T Yamada","year":"2025","unstructured":"Yamada T, Nakamura N, Goto H, et al. Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study. Ann Hematol. 2025;104(10):5191\u2013200. https:\/\/doi.org\/10.1007\/s00277-025-06619-0.","journal-title":"Ann Hematol"},{"issue":"4","key":"15584_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3727\/096504018x15267574931782","volume":"27","author":"T Saito","year":"2019","unstructured":"Saito T, Okamura A, Inoue J, et al. Anemia is a novel predictive factor for the onset of severe chemotherapy-induced peripheral neuropathy in lymphoma patients receiving Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Oncol Res. 2019;27(4):469\u201374. https:\/\/doi.org\/10.3727\/096504018x15267574931782.","journal-title":"Oncol Res"},{"issue":"5","key":"15584_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00520-024-08484-5","volume":"32","author":"T Li","year":"2024","unstructured":"Li T, Trinh T, Bosco A, et al. Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes. Support Care Cancer. 2024;32(5):278. https:\/\/doi.org\/10.1007\/s00520-024-08484-5.","journal-title":"Support Care Cancer"},{"issue":"2","key":"15584_CR34","doi-asserted-by":"publisher","first-page":"100077","DOI":"10.1016\/j.bneo.2025.100077","volume":"2","author":"T Nakashima","year":"2025","unstructured":"Nakashima T, Suzuki T, Machida R, et al. Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601. Blood Neoplasia. 2025;2(2):100077. https:\/\/doi.org\/10.1016\/j.bneo.2025.100077.","journal-title":"Blood Neoplasia"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15584-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:23:40Z","timestamp":1773224620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15584-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15584"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15584-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and was approved by the Matsunami General Hospital Medical Ethics Committee (Gifu, Japan) (approval number: 594). As this retrospective observational study used anonymized clinical data obtained from hospital medical records, the requirement for written informed consent was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain individual patient data, images, or other identifying clinical details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"336"}}